Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER-ALS Phase 1/2 study of VTx-002 in amyotrophic lateral sclerosis
2025-522697-37-00Phase 2Authorised
- Sponsor
- VectorY Therapeutics
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of tamuzimod in amyotrophic lateral sclerosis (ALS) (2 cohorts), sponsored by VectorY Therapeutics. Primary endpoints: Treatment-emergent adverse events, Laboratory safety assessments and 4 more. Planned start Jun 2026; status: authorised.
02
Drugs
tamuzimod
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2025-522697-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522697-37-00.